<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00138177</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00083</org_study_id>
    <secondary_id>NCI-2009-00083</secondary_id>
    <secondary_id>CDR0000439445</secondary_id>
    <secondary_id>I 55305</secondary_id>
    <secondary_id>6789</secondary_id>
    <nct_id>NCT00138177</nct_id>
  </id_info>
  <brief_title>Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors</brief_title>
  <official_title>A Phase I Study of Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX) in Patients With Colorectal Cancer and Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic&#xD;
      acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients&#xD;
      with progressive metastatic or unresectable colorectal cancer or solid tumor. Drugs used in&#xD;
      chemotherapy, such as suberoylanilide hydroxamic acid, fluorouracil, leucovorin, and&#xD;
      oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more&#xD;
      than one drug (combination chemotherapy) may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of suberoylanilide hydroxamic acid when administered&#xD;
      with fluorouracil, leucovorin calcium, and oxaliplatin in patients with progressive&#xD;
      metastatic or unresectable colorectal cancer or other solid tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity of this regimen in these patients. II. Determine the&#xD;
      pharmacokinetics of oxaliplatin, fluorouracil, and suberoylanilide hydroxamic acid in these&#xD;
      patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of suberoylanilide hydroxamic acid (SAHA).&#xD;
&#xD;
      Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin&#xD;
      IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV&#xD;
      over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression&#xD;
      or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of vorinostat</measure>
    <time_frame>2 weeks</time_frame>
    <description>Graded according to the NCI CTCAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 3, 4, or 5 adverse events graded using the NCI CTCAE version 4.0</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response, evaluated using the new international criteria proposed by the RECIST committee</measure>
    <time_frame>Up to 4 weeks after completion of study treatment</time_frame>
    <description>To be assigned a status of PR or CR, changes in tumor measurements must be confirmed by repeat assessments that should be performed 4 weeks or more after the criteria for response are first met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression studies for evidence of up-regulation or down-regulation, obtained from microarray testing and changes in expression patterns of TS</measure>
    <time_frame>Up to 4 weeks after completion of study treatment</time_frame>
    <description>Carried out with real time quantitative RT-PCR assays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis for vorinostat and 5-FU</measure>
    <time_frame>Days 1 and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DPD activity</measure>
    <time_frame>Up to 8 days after the first dose of vorinostat (course 1)</time_frame>
    <description>Tabulated by dose level.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage III Colon Cancer</condition>
  <condition>Stage III Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (vorinostat, mFOLFOX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral SAHA once or twice daily on days 1-3. Patients also receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 4 followed by fluorouracil IV over 46 hours on days 4-5. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of SAHA until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. A total of 10 patients are treated at the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, mFOLFOX)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, mFOLFOX)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Treatment (vorinostat, mFOLFOX)</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (vorinostat, mFOLFOX)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed colorectal cancer&#xD;
&#xD;
          -  Metastatic or unresectable disease OR diagnosis of solid tumor&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  ECOG 0-1 OR Karnofsky 70-100%&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No neuropathy &gt; grade 1&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biological composition to study drugs&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  Prior bevacizumab and/or cetuximab allowed&#xD;
&#xD;
          -  No concurrent routine or prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 2 weeks since prior valproic acid&#xD;
&#xD;
          -  No concurrent combination anti-retroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marwan Fakih</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>August 29, 2005</study_first_submitted>
  <study_first_submitted_qc>August 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2005</study_first_posted>
  <last_update_submitted>September 27, 2013</last_update_submitted>
  <last_update_submitted_qc>September 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

